NICE Draft Guidance Rejects Bayer’s Xofigo

The National Institute for Health and Care Excellence (NICE) today published draft regulatory guidance rejecting Bayer’s Xofigo for patients with prostate cancer. Xofigo has been submitted to the regulatory body to treat patients with hormone relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases. Clinical trials have demonstrated that Xofigo can significantly improve

Continue Reading

AstraZeneca’s Diabetes Drug, Xigduo, Launched in the UK

cialis Xigduo, Launched in the UK” src=”http://i39.tinypic.com/hwxyt2.jpg” width=”230″ height=”80″ />Type II diabetes patients living in England and Wales have gained access to a new treatment option to improve blood glucose levels after AstraZeneca launched their diabetes drug, Xigduo, earlier this week. Xigduo combines BMS-512148 and metformin in a twice-daily tablet for use in patients inadequately

Continue Reading

Eli Lilly Reveal Positive Clinical Trial Results for Dulaglutide

Eli Lilly has announced the results of their head-to-head clinical study which demonstrates that their investigational GLP-1 glucagon-like peptide 1 receptor agonist, dulaglutide,  is just as effective as Novo Nordisk’s Victoza, the market-leader in the area. The pharmaceutical company revealed the positive top-line results of the sixth clinical trial in their AWARD programme, whereby once-weekly

Continue Reading

Germany to Review Price of Eisai’s Fycompa

Epilepsy patients in Germany may gain access to Eisai’s drug, Fycompa, again after Germany’s Federal Joint Committee agreed to take another look at the drug’s pricing. Last year, Eisai announced that they would be withdrawing Fycompa (perampanel) from the German market as opposed to selling the epilepsy drug at the price approved by the Germany’s

Continue Reading

ViiV’s HIV Drug, Tivicay, Launched in the UK

diagnosis Tivicay, Launched in the UK” src=”http://i57.tinypic.com/2re6t69.jpg” width=”164″ height=”147″ />HIV patients in the UK will from this week have another treatment option after ViiV Healthcare announced the launch of their once-daily drug, Tivicay (dolutegravir). The integrase inhibitor was approved in Europe last month for HIV-1 in a broad patient population of treatment-naive and treatment-experienced adults

Continue Reading

Positive Clinical Study Results for Pfizer’s Chantix

Pfizer announced yesterday that Chantix/Champix (varenicline) has been shown to help smokers unable to quit ‘cold turkey’ kick their habit by slowly reducing the amount of cigarettes they smoke. The initial clinical study to assess the drug demonstrated that Chantix/Champix helped improve abstinence rates, in people wanting to reduce smoking prior to quitting.

Continue Reading

Auxilium Pharmaceuticals’ Xiaflex Approved by FDA

The US Food and Drug Administration (FDA) announced on Friday that they have approved Auxilium Pharmaceuticals’ Xiaflex to treat Peyronie’s disease, which causes painful, curved erections in men. Xiaflex (collagenase clostridium histolyticum) is the first FDA-approved non-surgical treatment option for men with Peyronie’s disease, who have a plaque in the penis that results in curvature

Continue Reading